What is Allogene Therapeutics's stock issuance proceeds?

Allogene Therapeutics (ALLO) reported stock issuance proceeds of $450K in Q1 2026.

How has Allogene Therapeutics's stock issuance proceeds changed year-over-year?

Allogene Therapeutics's stock issuance proceeds decreased by 95.5% year-over-year, from $10M to $450K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Allogene Therapeutics ALLO Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Gilead SciencesGILD

$166M-34.1%

PrecigenPGEN

$0+100%

CRISPR TherapeuticsCRSP

-$722K-108%

Sana BiotechnologySANA

$59K-94.8%

CytomX TherapeuticsCTMX

$228.35M—

Immix Biopharma, Inc.IMMX

$33.53K—

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's stock issuance proceeds?: Allogene Therapeutics (ALLO) reported stock issuance proceeds of $450K in Q1 2026.
How has Allogene Therapeutics's stock issuance proceeds changed year-over-year?: Allogene Therapeutics's stock issuance proceeds decreased by 95.5% year-over-year, from $10M to $450K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.